Search results
Showing 1156 to 1170 of 2006 results for nice guidelines
Four commonly used methods to increase physical activity (PH2)
This guideline covered four common methods used to increase the population's physical activity levels: brief interventions in primary care, exercise referral schemes, pedometers and community-based walking and cycling programmes. It has been updated and replaced by the following NICE guidelines: Walking and cycling (2012) PH41 Physical activity: brief advice for adults in primary care (2013) PH44 Exercise referral schemes to promote physical activity (2014) PH54
MiraQ for assessing graft flow during coronary artery bypass graft surgery (HTG275)
Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
applicable) Why this is important:- The evidence review for the NICE guideline on hearing loss found a lack of evidence to...
This indicator covers tooth extractions due to decay for children admitted as inpatients to hospital, aged 10 years and under. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Tegaderm CHG securement dressing for vascular access sites (MIB231)
NICE has developed a medtech innovation briefing (MIB) on Tegaderm CHG securement dressing for vascular access sites .
NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .
This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) as part of the single technology appraisal and highly specialised technologies evaluations process. It explains what information NICE requires and the format in which it should be presented
Early value assessment (EVA) guidance on the Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)
Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.
Evidence-based recommendations on bempedoic acid with ezetimibe (Nilemdo and Nustendi) for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults.
EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)
NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration
Low-energy contact X-ray brachytherapy for rectal cancer (HTG763)
Evidence-based recommendations on low-energy contact X-ray brachytherapy for rectal cancer. This involves inserting an X-ray tube through the anus into the rectum. The tube is placed in contact with the tumour and releases a low dose of X-ray radiation (brachytherapy) directly to it.
Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.